Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 08, 2024 16:02 ET | Source: Olema Oncology

Olema Oncology Reports First Quarter 2024 Financial Results and Provides Corporate Update

Completed enrollment in 60-patient Phase 1b/2 clinical studies of palazestrant in combination with each of ribociclib and palbociclibNew clinical data from palazestrant-ribociclib combination study to...
March 06, 2024 07:03 ET | Source: Olema Oncology

Olema Oncology Announces Publication of Data Highlighting Palazestrant’s Ability to Inhibit Wild-Type and Mutant ER+ Breast Cancer Both as Monotherapy and in Combination with CDK4/6 Inhibitors

Data published in Molecular Cancer Therapeutics describes the scientific background underlying the design, discovery and optimization of palazestrant (OP-1250)Pre-clinical results demonstrate that...
August 08, 2023 16:03 ET | Source: Olema Oncology

Olema Oncology Reports Second Quarter 2023 Financial Results and Provides Corporate Update

Initiation of OPERA-01 pivotal Phase 3 monotherapy clinical trial on track; expecting to enroll first patient in fourth quarterNew clinical data for palazestrant (OP-1250) to be presented in the...